Authors
Latest:
Complementary and Alternative Medicine Provider Use and Expenditures by Cancer Treatment PhaseMore than 26% of cancer patients see CAM providers, primarily for musculoskeletal problems; use does not vary by treatment phase, and associated expenditures are low.
Latest:
Rates of Thrombosis in Patients Treated With Hydroxyurea Fairly Stable Over Time, Review FindsMortality and myelofibrosis varied depending on follow-up duration in this review of patients with polycythemia vera treated with hydroxyurea, and incidences of thrombosis and acute myeloid leukemia (AML) were stable over time.
Latest:
Can a Nationwide Media Campaign Affect Antibiotic Use?A nationwide media campaign aimed at parents was associated with reductions in the use of antibiotics for pediatric upper respiratory infections, otitis media, and pharyngitis.
Latest:
Project ECHO: An Effective Means of Increasing Palliative Care CapacityThis article provides insight on the work of 7 of Project ECHO’s replicating partners from around the world who are implementing the ECHO model to address the knowledge gap that underlies integrated palliative care crisis.
Latest:
Effect of a Managed Care Disease Management Program on Diabetes CareProcesses and outcomes of diabetes care improved substantially over 6 years in a managed care health plan with a comprehensive diabetes disease management program.
Latest:
Assessing Outcomes in Child PsychiatryTwo standardized rating scales appeared to be valid and reliable for use at admission and possibly follow-up in a child psychiatry system of care.
Latest:
Pattern of Statin Use Among 10 Cohorts of New Users From 1995 to 2004: A Register-Based Nationwide StudyOne-year persistence among new users of statins in Finland improved from 1995 to 1998, after which no substantial changes were observed up to 2004.
Latest:
Decision Aids for Benign Prostatic Hyperplasia and Prostate CancerImplementing patient decision aids was associated with lower rates of elective surgery for benign prostatic hyperplasia and of active treatment for localized prostate cancer.
Latest:
Cost Analysis of COPD Exacerbations and Cardiovascular Events in SUMMITThis cost analysis using data from the Study to Understand Mortality and Morbidity in COPD (SUMMIT) trial found that fluticasone furoate/vilanterol reduced the rates and costs of combined chronic obstructive pulmonary disease (COPD) exacerbations and revascularization/cardiovascular events versus placebo.
Latest:
The Effect of Narrow Network Plans on Out-of-Pocket CostThe authors examined the effect of narrow network plan selection on beneficiaries’ outpatient visits and outpatient out-of-pocket expenditures in the 2014 nongroup health insurance market.
